Lupin Limited has announced the US launch of authorized generic version of Horizon Pharma Therapeutics’ PENNSAID (Diclofenac Sodium Topical Solution), 2% w/w.

Diclofenac Sodium Topical Solution is indicated for the treatment of arthritis of the knee.

Citing data from IQVIA MAT October 2022, the Indian pharma company said that the estimated annual sales of Diclofenac Sodium Topical Solution, 2% w/w in the US are $509 million.

  Arthritis, Diclofenac Sodium Topical Solution, Horizon Pharma Therapeutics, Lupin, PENNSAID, USA